Literature DB >> 6386025

Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects.

J A Millar, R Fraser, P Mason, B Leckie, A M Cumming, J I Robertson.   

Abstract

Amiloride (75 mg daily) and spironolactone (300 mg daily) were given to five normal subjects for 7 days in order to compare metabolic effects at maximal doses. Blood pressure, body weight, Na+ and K+ balance, and plasma concentrations of Na+, K+, active and total renin, angiotensin II, aldosterone, 11-deoxycorticosterone (DOC), 18-hydroxydeoxycorticosterone (18-OH DOC), corticosterone (B), 18-hydroxycorticosterone (18-OH B) and cortisol were measured before and on each day of treatment. Natriuresis and K+ retention were significantly greater with amiloride. Plasma K+ increased from 4.1 +/- 0.2 to 4.9 +/- 0.2 mmol/l (mean +/- s.d.) on amiloride and from 4.0 +/- 0.2 to 4.4 +/- 0.2 mmol/l with spironolactone. Stimulation of renin, angiotensin II, aldosterone and 18-OH B occurred with both drugs but was greater with amiloride in each case. A transient decrease in systolic and diastolic blood pressure was observed after 2 days of spironolactone treatment but not with amiloride. The slope of the regression of aldosterone on angiotensin II during spironolactone treatment was less than that with amiloride, consistent with partial blockade of aldosterone synthesis by spironolactone. These data suggest that the maximum metabolic effects of amiloride exceed those of spironolactone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386025      PMCID: PMC1463638          DOI: 10.1111/j.1365-2125.1984.tb02478.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Amiloride in the treatment of primary hyperaldosteronism and essential hypertension.

Authors:  D Kremer; K Boddy; J J Brown; D L Davies; R Fraser; A F Lever; J J Morton; J I Robertson
Journal:  Clin Endocrinol (Oxf)       Date:  1977-08       Impact factor: 3.478

2.  Estimation of 18-hydroxycorticosterone concentration in human peripheral plasma by gas-liquid chromatography with electron capture detection.

Authors:  A Wilson; P A Mason; R Fraser
Journal:  J Steroid Biochem       Date:  1976-08       Impact factor: 4.292

3.  Spironolactone-induced inhibition of aldosterone biosynthesis in primary aldosteronism: morphological and functional studies.

Authors:  J W Conn; D L Hinerman
Journal:  Metabolism       Date:  1977-12       Impact factor: 8.694

4.  Stimulation of aldosterone production in vitro and its inhibition by spironolactone.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

5.  Estimation of angiotensin II concentration in human plasma by radioimmunoassay. Some applications to physiological and clinical states.

Authors:  G Düsterdieck; G McElwee
Journal:  Eur J Clin Invest       Date:  1971-11       Impact factor: 4.686

6.  Clinical evaluation of amiloride, a potassium-sparing diuretic.

Authors:  A F Lant; A J Smith; G M Wilson
Journal:  Clin Pharmacol Ther       Date:  1969 Jan-Feb       Impact factor: 6.875

7.  Amiloride. A potassium-sparing natriuretic agent.

Authors:  M B Bull; J H Laragh
Journal:  Circulation       Date:  1968-01       Impact factor: 29.690

8.  Estimation of aldosterone, 11-deoxycorticosterone, 18-hydroxy-11-deoxy-corticosterone, corticosterone, cortisol and 11-deoxycortisol in human plasma by gas-liquid chromatography with electron capture detection.

Authors:  P A Mason; R Fraser
Journal:  J Endocrinol       Date:  1975-02       Impact factor: 4.286

9.  Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.

Authors:  S C Cheng; K Suzuki; W Sadee; B W Harding
Journal:  Endocrinology       Date:  1976-10       Impact factor: 4.736

10.  Agonist and antimineralocorticoid activities of spirolactones.

Authors:  C Sakauye; D Feldman
Journal:  Am J Physiol       Date:  1976-07
View more
  2 in total

1.  The acute effects of amiloride and potassium canrenoate on digoxin-induced positive inotropism in healthy volunteers.

Authors:  J P Richter; D K Sommers; J R Snyman; S M Millard
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models.

Authors:  Enrica Balza; Sebastiano Carlone; Sonia Carta; Patrizia Piccioli; Vanessa Cossu; Cecilia Marini; Gianmario Sambuceti; Anna Rubartelli; Patrizia Castellani
Journal:  Cancer Med       Date:  2021-11-18       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.